ClinicalTrials.gg
CompletedNCT03230786Updated Sep 11, 2018

Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes

A Phase 2 interventional study of Daily injection of KBP/placebo for 12 weeks as add-on to metformin in Type 2 Diabetes Mellitus, sponsored by KeyBioscience AG. Completed at 31 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-09-11.

Sponsored by KeyBioscience AG · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 249 studies in Diabetes Mellitus, Type 2 with a site in Czechia — 15 open to participants now, 24 under way, 20 of them phase 3. Diabetes Mellitus, Type 2 · Czechia.

Enrollment
189th of 234
255 · median 650
Started
2017
with 12 others
Phase 2
38 of 249
none open now
Registered
181st of 249
by date

Among the 249 studies in Diabetes Mellitus, Type 2 with a site in Czechia, this one is the 189th largest by enrollment of the 234 interventional ones that give a count, is one of 13 that started in 2017, is one of 38 in phase 2, and was the 181st registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 249 studies in Diabetes Mellitus, Type 2 with a site in Czechia are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies in Diabetes Mellitus, Type 2 with a site in Czechia, or all of them as a file.
02

Study summary

This is a multicentre, randomized, double-blind, placebo-controlled, parallel-group Phase II trial of twelve weeks of KBP-042 administered as daily s.c. injections in subjects with Type 2 Diabetes Mellitus with inadequate glycaemic control while treated with a stable dose of metformin.

The trial is planned to be performed in Czech Republic, Denmark, Moldova, Poland, Romania and United Kingdom

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Type 2 Diabetes Mellitus
  • KBP-042
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects, 18-75 years of age, both inclusive, at the time of the first screening visit. Women must be either using adequate, highly effective methods of , be or be considered sterile due to tubal ligation or other surgical procedures at the time of randomization. Sexually active men with a female partner of must agree in the use of highly effective method of contraception by the female partner throughout the trial period.
  2. Subjects with type 2 diabetes mellitus diagnosis whose levels are ≥7.0% and ≤10.0% (53 mmol/mol to 86 mmol/mol, respectively) at screening.
  3. Stable therapy (for at least 90 days prior to randomization) with metformin.
  4. (BMI) ≥ 25.0 kg/m², and ≤ 45.0 kg/m².
  5. The subject is able to understand and comply with protocol requirements.
  6. The subject is able and willing to give written .

Exclusion criteria

Exclusion Criteria:

  1. Investigator considering the subject inappropriate for inclusion in the study based on medical interview and/or physical examination.
  2. Past or present significant co-morbidity (other than type 2 diabetes mellitus) including, but not limited to: Active liver disease (other than asymptomatic non-alcoholic fatty liver disease), significant renal disease (including \< 45 ml/min by the Modification of Diet in Renal Disease () method, congestive heart failure ( class III or IV), myocardial infarction within the past 12 months, unstable angina pectoris.
  3. Prior treatment in clinical trials with dual amylin and calcitonin receptor agonists (DACRAs).
  4. Currently receiving medical treatment for obesity.
  5. History of bariatric surgery.
  6. Current alcohol abuse.
  7. Current medical non-metformin anti-diabetic therapy, including SGLT2-inhibitors, DPP4-inhibitors (dipeptidyl peptidase 4 inhibitors), GLP-1 (Glucagon-like peptide 1) analogues, insulin and sulfonylureas, for a period of 90 days prior to randomization.
  8. Use of thiazolidinediones (glitazones) lasting for more than one month within 90 days of randomization.
  9. Regular use of insulin or insulin analogues.
  10. History or presence of sensitivity or allergy to the study drug or drugs, to their components, or drugs of these classes or a history of drug or other allergy that contraindicates participation.
  11. History of sarcoma or other within the past five years, except adequately treated basal cell or squamous cell carcinoma of the skin, or resected cervical atypia or carcinoma in situ.
  12. Participation in a study trial with any new drug (new chemical entity) within 90 days prior to the start of the study.
  13. Pregnant females as determined by positive serum or urine human chorionic gonadotropin (hCG) test at screening or prior to randomization or during the treatment phase of the trial.
  14. Breast-feeding women.
  15. Known positive test results for antibodies, surface antigen, and at screening.
  16. (alanine transaminase) or AST (aspartat transaminase) > 2.5 times the at screening or other liver function test abnormalities.
  17. Clinically significant abnormalities, as judged by the investigator.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
255 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo QD for 12 weeks as add-on to metformin

    Drug: Daily injection of KBP/placebo for 12 weeks as add-on to metformin

  • Experimental
    15µg KBP-042 QD

    Up to 15µg KBP-042 QD for 12 weeks as add-on to metformin

    Drug: Daily injection of KBP/placebo for 12 weeks as add-on to metformin

  • Experimental
    30µg KBP-042 QD

    Up to 30µg KBP-042 QD for 12 weeks as add-on to metformin

    Drug: Daily injection of KBP/placebo for 12 weeks as add-on to metformin

  • Experimental
    50µg KBP-042 QD

    Up to 50µg KBP-042 QD for 12 weeks as add-on to metformin

    Drug: Daily injection of KBP/placebo for 12 weeks as add-on to metformin

Interventions

  • DrugDaily injection of KBP/placebo for 12 weeks as add-on to metformin

    Daily subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Change from baseline in blood HbA1c at 12 weeks versus placebo.

    Time frame: At 12 weeks

Secondary outcomes

  1. Change from baseline in body weight at 12 weeks versus placebo.

    Time frame: At 12 weeks

  2. Change from baseline in fasting serum glucose at 12 weeks versus placebo

    Time frame: At 12 weeks

  3. Change from baseline in fasting serum insulin at 12 weeks versus placebo

    Time frame: At 12 weeks

  4. Change from baseline in fasting serum glucagon at 12 weeks versus placebo

    Time frame: At 12 weeks

  5. Proportion of subjects reaching a level of HbA1c below 7.0% (53 mmol/mol) at 12 weeks versus placebo

    Time frame: At 12 weeks

07

Study locations

31 sites
  • Vdoviak Miroslav MUDr. - Interní Ambulance
    Karlovy Vary, 360 17, Czechia
  • General University Hospital
    Prague 2, 128 00, Czechia
  • Institute for Clinical and experimental Medicine
    Praha 4, 140 21, Czechia
  • Interní a Diabetologická ambulance, Clintrial s.r.o
    Praha, 100 00, Czechia
  • Endokrinologicky Ústav
    Praha, 113 94, Czechia
  • Diabet2 s.r.o
    Praha, Czechia
  • Interní a Diabetologická ambulance
    Uherské Hradiště, 68 601, Czechia
  • Diabetologická a Obezitologická ambulance
    České Budějovice, Czechia
  • Bispebjerg Hospital, Endokrinologisk Afdeling
    Bispebjerg, Copenhagen NV 2400, Denmark
  • Bioclinica
    Ballerup, Copenhagen 2750, Denmark
  • Bioclinica
    Aalborg, Jutland 9000, Denmark
  • Aarhus University Hospital, Endocrinlogy Department
    Aarhus, Jutland 8000, Denmark
  • Sydvestjysk Sygehus
    Esbjerg, Jutland 6700, Denmark
  • Bioclinica
    Vejle, Jutland 7100, Denmark
  • Holbæk Sygehus
    Holbæk, 4300, Denmark
  • Rtl Sm Srl/Scr
    Chisinau, MD2025, Moldova, Republic of
  • Rtl Sm Srl
    Chisinau, MD2025, Moldova, Republic of
  • Centrum Badań Klinicznych PI-House sp. z o.o.
    Gdańsk, 80-546, Poland
  • Specjalistyczna Praktyka Lekarska Piotr Kubalski
    Grudziądz, 86-302, Poland
  • Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczno
    Kraków, 31-261, Poland
  • Prywatny Gabinet Lekarski M. Horodecki (budynek Medicus)
    Opole, 45-367, Poland
  • Centrum Medyczne Hygea
    Tychy, 43-100, Poland
  • Centrum Medyczne AMED
    Warsaw, 01-518, Poland
  • Prywatny Gabinet Lekarski i Wizyty Lekarskie Jan Ruxer
    Łódź, 90-074, Poland
  • S.C. Policlinica CCBR S.R.L.
    Bucharest, 030463, Romania
  • Institutului Național de Diabet, Nutriție și Boli Metabolice "Prof.Dr. N.C. Paulescu"
    Bucharest, Romania
  • S.C Nicodiab S.R.L.
    Bucharest, Romania
  • S.C. Sfinx Medica S.R.L.
    Constanţa, 900412, Romania
  • S.C. Mediab S.R.L.
    Targu Mures, Romania
  • S.C. Mediab S.R.L.
    Târgu-Mureş, Romania
  • St. Pancras
    London, WC1X 8QD, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Not to be shared

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Jul 2018, 10 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 10 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2017
First posted
Jul 26, 2017
StartActual
Aug 23, 2017
Primary completionActual
Jul 9, 2018
CompletionActual
Jul 31, 2018
Last update
Sep 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03230786
Lead sponsor
KeyBioscience AG
Collaborators
Nordic Bioscience A/S
Responsible party
Sponsor
First posted
Jul 26, 2017
Start date
Aug 23, 2017
Primary completion
Jul 9, 2018
Completion
Jul 31, 2018
Last update
Sep 11, 2018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion